CN116354599A - Boron-containing bioactive glass and preparation method and application thereof - Google Patents
Boron-containing bioactive glass and preparation method and application thereof Download PDFInfo
- Publication number
- CN116354599A CN116354599A CN202310406166.2A CN202310406166A CN116354599A CN 116354599 A CN116354599 A CN 116354599A CN 202310406166 A CN202310406166 A CN 202310406166A CN 116354599 A CN116354599 A CN 116354599A
- Authority
- CN
- China
- Prior art keywords
- parts
- boron
- bioactive glass
- containing bioactive
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005313 bioactive glass Substances 0.000 title claims abstract description 86
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 46
- 229910004298 SiO 2 Inorganic materials 0.000 claims abstract description 12
- 208000008960 Diabetic foot Diseases 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 55
- 206010052428 Wound Diseases 0.000 claims description 43
- 230000029663 wound healing Effects 0.000 claims description 25
- 239000002994 raw material Substances 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 12
- 229940099259 vaseline Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 45
- 238000012360 testing method Methods 0.000 description 29
- 239000011734 sodium Substances 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 239000010949 copper Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 239000011575 calcium Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 229910019440 Mg(OH) Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- -1 NaHCO 3 Substances 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000029774 keratinocyte migration Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100496858 Mus musculus Colec12 gene Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229910004283 SiO 4 Inorganic materials 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000005297 material degradation process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 229910001427 strontium ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/062—Glass compositions containing silica with less than 40% silica by weight
- C03C3/064—Glass compositions containing silica with less than 40% silica by weight containing boron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Geochemistry & Mineralogy (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明涉及本生物材料技术领域，具体涉及一种含硼生物活性玻璃及其制备方法与应用。The invention relates to the technical field of biomaterials, in particular to a boron-containing bioactive glass and its preparation method and application.
背景技术Background technique
全球超过670万患者患有慢性创面，慢性创面的治疗一直也是临床伤口护理的难题，其病程冗长，常引起严重功能障碍，给病人造成极大的痛苦和不便。伤口护理生物材料从传统的棉纱敷料、矿物质和软膏等发展到现如今包含水凝胶、海绵、泡沫、纤维、喷雾、甚至于细胞和生长因子的高级皮肤替代物，但它们仍无法恢复受伤区域原生宿主皮肤的完整结构和生理机能，或者缺乏皮肤附属器官再生，离理想的伤口护理材料仍显差距。如何寻找合理治疗方案以促进慢性创面快速修复成为临床工作中亟需解决的问题。More than 6.7 million patients around the world suffer from chronic wounds, and the treatment of chronic wounds has always been a difficult problem in clinical wound care. The disease course is lengthy and often causes severe dysfunction, causing great pain and inconvenience to patients. Wound care biomaterials have evolved from traditional gauze dressings, minerals, and ointments to today's advanced skin substitutes that include hydrogels, sponges, foams, fibers, sprays, and even cells and growth factors, but they still can't heal injuries The complete structure and physiology of the regional native host skin, or the lack of regeneration of skin appendages, is still far from an ideal wound care material. How to find a reasonable treatment plan to promote the rapid repair of chronic wounds has become an urgent problem in clinical work.
生物活性玻璃是一种无机合成材料，保质期可长达3年，对人体几乎无明显毒性和副作用，目前该种材料广泛用于骨科手术、骨缺损
因此提供一种有利于急性/慢性大创面的有效修复与重建的材料，是当务之急。Therefore, it is urgent to provide a material that is beneficial to the effective repair and reconstruction of acute/chronic large wounds.
发明内容Contents of the invention
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此，本发明提出一种含硼生物活性玻璃，通过原料间的合成，实现了含硼生物活性玻璃对糖尿病足、褥疮、烧伤和各种类型皮肤表面溃疡等大面积创面的治疗。The present invention aims to solve at least one of the technical problems in the above-mentioned prior art. For this reason, the present invention proposes a boron-containing bioactive glass, which realizes the treatment of large-area wounds such as diabetic foot, decubitus, burns and various types of skin surface ulcers through the synthesis of raw materials.
根据本发明的第一方面的实施例，提出了一种含硼生物活性玻璃，按摩尔份数计，包括如下组分：B2O3 20-30份、SiO220-30份、CaO 20-30份、MgO 6-8份、SrO 6-8份、Na2O 2-3份、K2O 2-5份和P2O5 2-4。According to the embodiment of the first aspect of the present invention, a boron-containing bioactive glass is proposed, which comprises the following components in molar parts: 20-30 parts of B 2 O 3 , 20-30 parts of SiO 2 , 20 parts of CaO -30 parts, MgO 6-8 parts, SrO 6-8 parts, Na 2 O 2-3 parts, K 2 O 2-5 parts and P 2 O 5 2-4 parts.
根据本发明的第一方面的实施例，至少具有以下有益效果：According to the embodiment of the first aspect of the present invention, it has at least the following beneficial effects:
1.本发明的含硼生物活性玻璃生物相容性优良、可调控性强，具有促愈合功效，通过各元素比例调控，材料降解所形成的生物活性微环境可显著加速创面伤口的愈合，加速上皮组织中角化细胞的迁移，以本发明的含硼生物活性玻璃为原料的促创面愈合材料可显著促进SD大鼠背部全层皮肤大缺损(20mm)愈合速度，加速皮肤收缩，促进皮肤再上皮化；在糖尿病大鼠创面全层皮肤大缺损(20mm)愈合情况下，可有效促进创面角化细胞迁移，加速创面愈合。1. The boron-containing bioactive glass of the present invention has excellent biocompatibility, strong controllability, and has the effect of promoting healing. Through the regulation of the ratio of each element, the bioactive microenvironment formed by material degradation can significantly accelerate the healing of wounds, accelerate The migration of keratinocytes in the epithelial tissue, the material for promoting wound healing with the boron-containing bioactive glass of the present invention as raw material can significantly promote the healing speed of the large defect (20mm) of the full-thickness skin on the back of SD rats, accelerate skin contraction, and promote skin regeneration. Epithelialization: In the case of healing of large full-thickness skin defects (20mm) in diabetic rat wounds, it can effectively promote the migration of wound keratinocytes and accelerate wound healing.
2.基于糖尿病等慢性创面难愈合关键原因之一是创面处于持续的炎症过程，病理性伤口创面以炎症M1型巨噬细胞为主，而含硼生物活性玻璃在降解过程中产生离子微环境，其中的硼酸根([BO3]3-)可通过调控巨噬细胞的极化作用，加速巨噬细胞向抗炎M2表型转变，提高创面组织的抗炎活性，硅酸根(SiO4 4-)、钙离子(Ca2+)、镁离子(Mg2+)、锶离子(Sr2 +)可以诱导和促进血管的形成，锌离子(Zn2+)和铜离子(Cu2+)具备抑菌功能，可降低伤口感染，同时[BO3]3-、Ca2+等可通过上调角化细胞迁移相关基因K-10、K-14和Involucrin，加速再上皮化，从而在创面愈合的不同阶段促进愈合，缩短愈合时间。2. One of the key reasons why chronic wounds such as diabetes are difficult to heal is that the wound is in a continuous inflammatory process. Pathological wounds are dominated by inflammatory M1 macrophages, and boron-containing bioactive glass generates an ion microenvironment during the degradation process. The borate ([BO 3 ]3-) can accelerate the transformation of macrophages to the anti-inflammatory M2 phenotype by regulating the polarization of macrophages, and improve the anti-inflammatory activity of wound tissue. Silicate (SiO 4 4- ), calcium ions (Ca 2+ ), magnesium ions (Mg 2+ ), strontium ions (Sr 2 + ) can induce and promote the formation of blood vessels, zinc ions (Zn 2+ ) and copper ions (Cu 2+ ) have inhibitory Bacterial function, can reduce wound infection, at the same time [BO 3 ]3-, Ca 2+ , etc. can accelerate re-epithelialization by up-regulating keratinocyte migration-related genes K-10, K-14 and Involucrin, thus playing a role in different wound healing Phases promote healing and shorten healing time.
3.本发明的含硼生物活性玻璃生物安全性良好，无明显细胞毒性，血液相容性良好。3. The boron-containing bioactive glass of the present invention has good biological safety, no obvious cytotoxicity, and good blood compatibility.
根据本发明的一些实施例，摩尔份数计，所述含硼生物活性玻璃包括如下组分：B2O326-28份、SiO226-28份、CaO 22-24份、MgO 7-8份、SrO 6-7份、Na2O 2-3份、K2O 4-5份和P2O5 2-3份。According to some embodiments of the present invention, in terms of mole fractions, the boron-containing bioactive glass includes the following components: B 2 O 3 26-28 parts, SiO 2 26-28 parts, CaO 22-24 parts, MgO 7- 8 parts, SrO 6-7 parts, Na 2 O 2-3 parts, K 2 O 4-5 parts and P 2 O 5 2-3 parts.
本发明的含硼生物活性玻璃，硼占比小、成本低廉、操作简单，可大大降低急、慢性创面的救治费用。The boron-containing bioactive glass of the present invention has a small proportion of boron, low cost and simple operation, and can greatly reduce the treatment cost of acute and chronic wounds.
根据本发明的一些实施例，所述含硼生物活性玻璃的制备原料还包括ZnO。According to some embodiments of the present invention, the raw material for preparing the boron-containing bioactive glass further includes ZnO.
根据本发明的一些实施例，所述含硼生物活性玻璃的制备原料还包括CuO。According to some embodiments of the present invention, the raw materials for preparing the boron-containing bioactive glass further include CuO.
锌离子(Zn2+)、铜离子(Cu2+)可以诱导和促进血管的形成，在创面愈合的不同阶段促进愈合，缩短愈合时间。Zinc ions (Zn 2+ ) and copper ions (Cu 2+ ) can induce and promote the formation of blood vessels, promote healing in different stages of wound healing, and shorten the healing time.
根据本发明的一些实施例，摩尔份数计，所述含硼生物活性玻璃包括如下组分：B2O320-30份、SiO220-30份、CaO 20-30份、MgO 6-8份、SrO 6-8份、ZnO 0.01-1份、CuO0.01-1份、Na2O 2-3份、K2O 2-5份和P2O5 2-4份。According to some embodiments of the present invention, in terms of mole fractions, the boron-containing bioactive glass includes the following components: 20-30 parts of B 2 O 3 , 20-30 parts of SiO 2 , 20-30 parts of CaO, 20-30 parts of MgO 6- 8 parts, SrO 6-8 parts, ZnO 0.01-1 parts, CuO 0.01-1 parts, Na 2 O 2-3 parts, K 2 O 2-5 parts and P 2 O 5 2-4 parts.
根据本发明的一些实施例，所述含硼生物活性玻璃的尺寸为20-60μm。According to some embodiments of the present invention, the size of the boron-containing bioactive glass is 20-60 μm.
根据本发明的第二方面的实施例，提出了一种所述的含硼生物活性玻璃的制备方法，包括以下步骤：将B源、Si源、Ca源、Mg源、Sr源Na源和K源和P源化合物混合。According to the embodiment of the second aspect of the present invention, a kind of preparation method of the boron-containing bioactive glass is proposed, comprising the following steps: B source, Si source, Ca source, Mg source, Sr source Na source and K source and P source compounds are mixed.
根据本发明的一些实施例，所述的含硼生物活性玻璃的制备方法，包括以下步骤：将B源、Si源、Ca源、Mg源、Sr源、Zn源、Cu源、P源、Na源和K源化合物混合。According to some embodiments of the present invention, the preparation method of the boron-containing bioactive glass includes the following steps: B source, Si source, Ca source, Mg source, Sr source, Zn source, Cu source, P source, Na source source and K source compounds are mixed.
根据本发明的一些实施例，所述混的温度为1000℃～1500℃。According to some embodiments of the present invention, the mixing temperature is 1000°C-1500°C.
根据本发明的一些实施例，所述混合包括，加热、冷却。According to some embodiments of the present invention, the mixing includes heating and cooling.
根据本发明的一些实施例，所述冷却的过程包括在冷的钢板上淬灭。According to some embodiments of the present invention, said cooling comprises quenching on a cold steel plate.
根据本发明的一些实施例，所述Si源包括SiO2。According to some embodiments of the present invention, the Si source includes SiO 2 .
根据本发明的一些实施例，所述B源包括H3BO3和Na2B4O7中的至少一种。According to some embodiments of the present invention, the B source includes at least one of H 3 BO 3 and Na 2 B 4 O 7 .
根据本发明的一些实施例，所述Ca源包括CaO、Ca(OH)2、CaCl2、Ca(HCO3)2和CaCO3中的至少一种。According to some embodiments of the present invention, the Ca source includes at least one of CaO, Ca(OH) 2 , CaCl 2 , Ca(HCO 3 ) 2 and CaCO 3 .
根据本发明的一些实施例，所述Mg源包括MgO、Mg(OH)2、(MgCO3)4·Mg(OH)2·5H2O和MgCl2中的至少一种。According to some embodiments of the present invention, the Mg source includes at least one of MgO, Mg(OH) 2 , (MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O and MgCl 2 .
根据本发明的一些实施例，所述Sr源包括SrO、SrCO3和SrCl2中的至少一种。According to some embodiments of the present invention, the Sr source includes at least one of SrO, SrCO 3 and SrCl 2 .
根据本发明的一些实施例，所述P源包括P2O5、H3PO4、Na3PO4、Na2HPO4和NaH2PO4·2H2O中的至少一种。According to some embodiments of the present invention, the P source includes at least one of P 2 O 5 , H 3 PO 4 , Na 3 PO 4 , Na 2 HPO 4 and NaH 2 PO 4 ·2H 2 O.
根据本发明的一些实施例，所述Na源包括Na2O、NaOH、NaHCO3、Na2CO3、Na2HPO4、NaH2PO4、Na3PO4和NaCl中的至少一种。According to some embodiments of the present invention, the Na source includes at least one of Na 2 O, NaOH, NaHCO 3 , Na 2 CO 3 , Na 2 HPO 4 , NaH 2 PO 4 , Na 3 PO 4 and NaCl.
根据本发明的一些实施例，所述K源包括K2O、KOH、KHCO3、K2CO3、K2HPO4、KH2PO4、K3PO4和KCl中的至少一种。According to some embodiments of the present invention, the K source includes at least one of K 2 O, KOH, KHCO 3 , K 2 CO 3 , K 2 HPO 4 , KH 2 PO 4 , K 3 PO 4 and KCl.
根据本发明的一些实施例，所述Zn源包括ZnO、ZnCO3、[ZnCO3]2·[Zn(OH)2]3和ZnCl2中的至少一种。According to some embodiments of the present invention, the Zn source includes at least one of ZnO, ZnCO 3 , [ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 and ZnCl 2 .
根据本发明的一些实施例，所述Cu源包括CuO、CuCO3·Cu(OH)2和ZnCl2中的至少一种。According to some embodiments of the present invention, the Cu source includes at least one of CuO, CuCO 3 ·Cu(OH) 2 and ZnCl 2 .
根据本发明的第三方面的实施例，提出了一种创面愈合材料，所述创面愈合材料的制备原料包括所述的含硼生物活性玻璃。According to an embodiment of the third aspect of the present invention, a wound healing material is proposed, and the preparation raw material of the wound healing material includes the boron-containing bioactive glass.
根据本发明的一些实施例，所述创面愈合材料的制备原料还包括抗生素、生长因子、止痛药和常规放化疗药物中的至少一种。According to some embodiments of the present invention, the raw materials for the preparation of the wound healing material further include at least one of antibiotics, growth factors, pain relievers and conventional chemoradiotherapy drugs.
根据本发明的一些实施例，所述创面愈合材料的剂型包括凝胶材料、软膏和油纱布中的至少一种。According to some embodiments of the present invention, the dosage form of the wound healing material includes at least one of gel material, ointment and oil gauze.
根据本发明的一些实施例，所述凝胶材料的制备原料还包括凡士林和石蜡。According to some embodiments of the present invention, the raw materials for the preparation of the gel material further include petrolatum and paraffin.
根据本发明的一些实施例，所述凝胶材料的制备原料还包括液体石蜡份、维生素E、保湿剂和抗氧化剂。According to some embodiments of the present invention, the raw materials for the preparation of the gel material further include liquid paraffin, vitamin E, moisturizing agent and antioxidant.
根据本发明的一些实施例，所述凡士林包括白凡士林。According to some embodiments of the present invention, the petrolatum includes white petrolatum.
根据本发明的一些实施例，所述石蜡包括液体石蜡。According to some embodiments of the present invention, the paraffin includes liquid paraffin.
本发明的凝胶材料，在上述组分下，具有良好的可注射性，可适用于各种不规则伤口的涂抹覆盖，可预防包扎所引起的组织与纱布等敷料黏连问题，且可有效阻隔细菌与组织的粘附。The gel material of the present invention, with the above components, has good injectability, can be applied to various irregular wounds, can prevent the adhesion of tissues and dressings such as gauze caused by bandaging, and can effectively Block the adhesion of bacteria to tissues.
根据本发明的一些实施例，按重量份计，所述凝胶材料的制备原料包括含硼生物活性玻璃0.1-10份，凡士林50-95份、石蜡0-10份、维生素E 0-5份、保湿剂0-5份和抗氧化剂0-0.2份。According to some embodiments of the present invention, in parts by weight, the preparation raw materials of the gel material include 0.1-10 parts of boron-containing bioactive glass, 50-95 parts of petrolatum, 0-10 parts of paraffin, and 0-5 parts of vitamin E. , 0-5 parts of moisturizing agent and 0-0.2 parts of antioxidant.
根据本发明的一些实施例，所述凝胶材料的制备方法包括将所述凝胶材料的制备原料混合。According to some embodiments of the present invention, the preparation method of the gel material includes mixing the preparation raw materials of the gel material.
根据本发明的一些实施例，所述凝胶材料的制备方法中，所述混合的温度为30-60℃。According to some embodiments of the present invention, in the preparation method of the gel material, the mixing temperature is 30-60°C.
根据本发明的一些实施例，所述凝胶材料的制备方法中，所述混合的方法包括搅拌。According to some embodiments of the present invention, in the preparation method of the gel material, the mixing method includes stirring.
本发明的凝胶材料的制备方法，至少具有以下有益效果：本发明原料经过简单的低温混合，以及搅拌即可获得匀质的含硼生物活性玻璃凝胶，该工艺原料廉价易得、可规模化生产。The preparation method of the gel material of the present invention has at least the following beneficial effects: the raw materials of the present invention can obtain a homogeneous boron-containing bioactive glass gel through simple low-temperature mixing and stirring, and the process raw materials are cheap, easy to obtain, and scalable. chemical production.
根据本发明的第四方面的实施例，提出了一种含硼生物活性玻璃在创面愈合中的应用。According to an embodiment of the fourth aspect of the present invention, an application of a boron-containing bioactive glass in wound healing is proposed.
根据本发明的一些实施例，所述创面包括慢性创面和急性创面。According to some embodiments of the present invention, the wound includes chronic wound and acute wound.
根据本发明的一些实施例，所述慢性创面包括糖尿病足创面。According to some embodiments of the present invention, the chronic wounds include diabetic foot wounds.
附图说明Description of drawings
下面结合附图和实施例对本发明做进一步的说明，其中：The present invention will be further described below in conjunction with accompanying drawing and embodiment, wherein:
图1为本发明的含硼生物活性玻璃凝胶材料的外观图；Fig. 1 is the external view of boron-containing bioactive glass gel material of the present invention;
图2为本发明的含硼生物活性玻璃凝胶材料的创面愈合情况；Fig. 2 is the wound healing situation of the boron-containing bioactive glass gel material of the present invention;
图3为本发明的含硼生物活性玻璃凝胶材料的创面愈合组织切片染色情况；Fig. 3 is the staining situation of the wound healing tissue section of the boron-containing bioactive glass gel material of the present invention;
图4为本发明的含硼生物活性玻璃凝胶材料的促进角化细胞迁移情况；Fig. 4 is the promotion situation of keratinocyte migration of the boron-containing bioactive glass gel material of the present invention;
图5为本发明的含硼生物活性玻璃凝材料的抑菌情况；Fig. 5 is the antibacterial situation of the boron-containing bioactive glass gel material of the present invention;
图6为本发明的含硼生物活性玻璃凝胶材料的细胞毒性；Fig. 6 is the cytotoxicity of the boron-containing bioactive glass gel material of the present invention;
图7为本发明的含硼生物活性玻璃凝胶材料的溶血率。Fig. 7 is the hemolysis rate of the boron-containing bioactive glass gel material of the present invention.
具体实施方式Detailed ways
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整地描述，以充分地理解本发明的目的、特征和效果。显然，所描述的实施例只是本发明的一部分实施例，而不是全部实施例，基于本发明的实施例，本领域的技术人员在不付出创造性劳动的前提下所获得的其他实施例，均属于本发明保护的范围。The conception and technical effects of the present invention will be clearly and completely described below in conjunction with the embodiments, so as to fully understand the purpose, features and effects of the present invention. Apparently, the described embodiments are only some of the embodiments of the present invention, rather than all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative efforts belong to The protection scope of the present invention.
实施例1Example 1
本实施例制备了一种含硼生物活性玻璃的凝胶材料，具体制备方法为：In this embodiment, a gel material containing boron-containing bioactive glass is prepared, and the specific preparation method is as follows:
S1：称取一定量H3BO3、SiO2、CaCO3、(MgCO3)4·Mg(OH)2·5H2O、SrCO3、[ZnCO3]2·[Zn(OH)2]3、CuCO3·Cu(OH)2、NaH2PO4·2H2O、无水Na2CO3和无水K2CO3以三元混合仪混合均匀，于1300℃下融化混合物，然后将熔融玻璃水在冷却的钢板上淬灭，得到按摩尔分数计为B2O320份、SiO234份、CaO16份、MgO 10份、SrO 5份、ZnO 1份、Na2O 5份、K2O 5份、P2O5 5份的含硼生物活性玻璃I，含硼生物活性玻璃的颗粒的尺寸为20-60μm。S1: Weigh a certain amount of H 3 BO 3 , SiO 2 , CaCO 3 , (MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O, SrCO 3 , [ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 , CuCO 3 ·Cu(OH) 2 , NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 and anhydrous K 2 CO 3 were mixed evenly with a ternary mixer, and the mixture was melted at 1300°C, and then the molten The glass water is quenched on the cooled steel plate to obtain 20 parts of B 2 O 3 , 34 parts of SiO 2 , 16 parts of CaO, 10 parts of MgO, 5 parts of SrO, 1 part of ZnO, 5 parts of Na 2 O, K 2 O 5 parts, P 2 O 5 5 parts boron-containing bioactive glass I, the particle size of the boron-containing bioactive glass is 20-60 μm.
S2：在60℃下，加热融化凡士林，然后按质量比，凡士林：含硼生物活性玻璃为9:1加入含硼生物活性玻璃，充分搅拌混合，关闭加热电源，继续搅拌直至降为室温。材料命名为含硼生物活性玻璃凝胶I，外观图如图1所示。S2: Heat and melt vaseline at 60°C, then add boron-containing bioactive glass according to the mass ratio of vaseline: boron-containing bioactive glass at a ratio of 9:1, stir and mix thoroughly, turn off the heating power supply, and continue stirring until the temperature drops to room temperature. The material is named boron-containing bioactive glass gel I, and its appearance is shown in Figure 1.
实施例2Example 2
本实施例制备了一种含硼生物活性玻璃的凝胶材料，具体制备方法为：In this embodiment, a gel material containing boron-containing bioactive glass is prepared, and the specific preparation method is as follows:
S1：称取一定量H3BO3、SiO2、CaCO3、(MgCO3)4·Mg(OH)2·5H2O、SrCO3、[ZnCO3]2·[Zn(OH)2]3、CuCO3·Cu(OH)2、NaH2PO4·2H2O、无水Na2CO3和无水K2CO3以三元混合仪混合均匀，于1300℃下融化混合物，然后将熔融玻璃水在冷却的钢板上淬灭，得到按摩尔分数计为B2O327份、SiO227份、CaO 23份、MgO 8份、SrO 6份、Na2O 3份、K2O 4份、P2O5 2份的含硼生物活性玻璃II，含硼生物活性玻璃的颗粒的尺寸为20-60μm。S1: Weigh a certain amount of H 3 BO 3 , SiO 2 , CaCO 3 , (MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O, SrCO 3 , [ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 , CuCO 3 ·Cu(OH) 2 , NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 and anhydrous K 2 CO 3 were mixed evenly with a ternary mixer, and the mixture was melted at 1300°C, and then the molten The glass water is quenched on the cooled steel plate to obtain 27 parts of B 2 O 3 , 27 parts of SiO 2 , 23 parts of CaO, 8 parts of MgO, 6 parts of SrO, 3 parts of Na 2 O , and K 2 O 4 in terms of mole fractions. Parts, P 2 O 5 2 parts of boron-containing bioactive glass II, the particle size of boron-containing bioactive glass is 20-60 μm.
S2：在50℃下，加热融化凡士林，然后按质量比例凡士林：含硼生物活性玻璃为50:1加入含硼生物活性玻璃，充分搅拌混合，关闭加热电源，继续搅拌直至降为室温。材料命名为含硼生物活性玻璃凝胶II。S2: Heat and melt vaseline at 50°C, then add boron-containing bioactive glass according to the mass ratio of vaseline: boron-containing bioactive glass 50:1, stir and mix thoroughly, turn off the heating power supply, and continue stirring until the temperature drops to room temperature. The material was named boron-containing bioactive glass gel II.
实施例3Example 3
本实施例制备了一种含硼生物活性玻璃的凝胶材料，具体制备方法为：In this embodiment, a gel material containing boron-containing bioactive glass is prepared, and the specific preparation method is as follows:
S1：称取一定量H3BO3、SiO2、CaCO3、(MgCO3)4·Mg(OH)2·5H2O、SrCO3、[ZnCO3]2·[Zn(OH)2]3、CuCO3·Cu(OH)2、NaH2PO4·2H2O、无水Na2CO3和无水K2CO3以三元混合仪混合均匀，于1300℃下融化混合物，然后将熔融玻璃水在冷却的钢板上淬灭，得到按摩尔分数计为B2O327份、SiO227份、CaO 22份、MgO 8份、SrO 6份、CuO 1份、Na2O 3份、K2O 4份、P2O5 2份的含硼生物活性玻璃III，含硼生物活性玻璃的颗粒的尺寸为20-60μm。S1: Weigh a certain amount of H 3 BO 3 , SiO 2 , CaCO 3 , (MgCO 3 ) 4 ·Mg(OH) 2 ·5H 2 O, SrCO 3 , [ZnCO 3 ] 2 ·[Zn(OH) 2 ] 3 , CuCO 3 ·Cu(OH) 2 , NaH 2 PO 4 ·2H 2 O, anhydrous Na 2 CO 3 and anhydrous K 2 CO 3 were mixed evenly with a ternary mixer, and the mixture was melted at 1300°C, and then the molten The glass water is quenched on the cooled steel plate to obtain 27 parts of B2O3 , 27 parts of SiO2, 22 parts of CaO, 8 parts of MgO, 6 parts of SrO, 1 part of CuO, 3 parts of Na2O , Boron-containing bioactive glass III with 4 parts of K 2 O and 2 parts of P 2 O 5 , the particle size of the boron-containing bioactive glass is 20-60 μm.
S2：在40℃下，加热融化凡士林，然后按质量比例凡士林：含硼生物活性玻璃为99:1加入含硼生物活性玻璃，充分搅拌混合，关闭加热电源，继续搅拌直至降为室温。材料命名为含硼生物活性玻璃凝胶III。S2: Heat and melt vaseline at 40°C, then add boron-containing bioactive glass at a mass ratio of vaseline: boron-containing bioactive glass of 99:1, stir and mix thoroughly, turn off the heating power, and continue stirring until the temperature drops to room temperature. The material was named boron-containing bioactive glass gel III.
对比例1Comparative example 1
本对比例制备了一种硅酸盐生物活性玻璃凝胶商业化产品(生物活性玻璃凝胶)，本对比例和实施例2的区别在于不包括硼，其余条件相同。In this comparative example, a commercial product of silicate bioactive glass gel (bioactive glass gel) was prepared. The difference between this comparative example and Example 2 is that boron is not included, and other conditions are the same.
对比例2Comparative example 2
本对比例制备了一种生物活性玻璃的凝胶材料，本对比例和实施例2的区别在于按摩尔分数计为B2O3 37份、SiO217份、CaO 23份、MgO 8份、SrO 6份、Na2O 3份、K2O 4份、P2O52份的含硼生物活性玻璃，其余条件相同。This comparative example prepared a gel material of bioactive glass. The difference between this comparative example and Example 2 is that the molar fractions are B 2 O 3 37 parts, SiO 17 parts, CaO 23 parts, MgO 8 parts, Boron-containing bioactive glass with 6 parts of SrO, 3 parts of Na 2 O, 4 parts of K 2 O, and 2 parts of P 2 O 5 , and the other conditions are the same.
测试例1test case 1
本测试例测试了不同材料的促正常创面伤口愈合情况的影响。This test case tests the effect of different materials on promoting normal wound healing.
SD大鼠体重约200-300g，雌雄不限每组各6只。实验前SD大鼠禁食12h。将SD大鼠以异氟烷进行气体麻醉，并对麻醉后的SD大鼠进行保温。在SD大鼠背部进行脱毛处理，然后用碘伏消毒，以圆形聚四氟乙烯环(内径20mm)确定直径为20mm的圆形术区，以手术剪造20mm全层皮肤缺损模型，并将圆形聚四氟乙烯环缝合在皮肤上，减小SD大鼠皮肤自生收缩对创面愈合的影响。每只SD大鼠背部两侧分别造一个创口。阴性空白对照组施加生理盐水，实验组为实施例1-3制备的含硼生物活性玻璃凝胶，阳性对照组为对比例1的生物活性玻璃凝；伤口涂抹材料后，分别用TegadermTM Film(3M)密封创面，然后采用弹力绷带固定伤口。每隔3-4日进行换药，观察创面愈合情况。图2可知，通过动物实验验证，与对照组相比，含硼生物活性玻璃凝胶I、II、III均具有良好的修复创面能力，可显著提高创面愈合的速度。The weight of SD rats is about 200-300g, and there are 6 rats in each group, whether male or female. SD rats were fasted for 12 h before the experiment. The SD rats were anesthetized with isoflurane gas, and the anesthetized SD rats were kept warm. Depilation was performed on the back of SD rats, and then disinfected with povidone iodine. A circular operation area with a diameter of 20 mm was determined with a circular polytetrafluoroethylene ring (
测试例2
本测试例测试了不同材料的促进糖尿病创面愈合情况的影响。This test case tests the effect of different materials on promoting diabetic wound healing.
SD大鼠体重约300-400g，雄鼠每组各6只。实验前SD大鼠禁食12h。根据SD大鼠体重55mg/kg剂量腹腔注射链脲佐菌素，10天后SD大鼠呈现高血糖(>16.7mmol/L)、体重减轻、多饮多食多尿的特点，成功构建I型糖尿病大鼠模型。将造模成功的糖尿病SD大鼠在饲养45天后，进行皮肤创面愈合实验。采用异氟烷对糖尿病SD大鼠进行气体麻醉。在糖尿病SD大鼠背部脱毛处理，碘伏消毒，以圆形模具在背部双侧创制2个内径20mm全层皮肤缺损模型。阴性空白对照组施加生理盐水，实验组为实施例1-3制备的含硼生物活性玻璃凝胶，阳性对照组为不含生物活性玻璃凝胶和对比例1的生物活性玻璃凝胶；伤口涂抹材料后，分别用TegadermTM Film(3M)密封创面，然后采用弹力绷带固定伤口。每隔3-4日进行换药，观察创面愈合情况。在3天、7天、14天和21天分别进行伤口部位组织的HE染色。图3的HE染色结果表明，相比于对照组，实施例2所制备的含硼生物活性玻璃不仅可以显著促进伤口收缩(图2)，而且可以在第3天时显著促进上皮细胞形成(图3)，在实施例2的伤口损伤处在3天时可看到连续的一定厚度的再上皮化组织，而其它对照组和实验组伤口处均未形成；而且在21天，实施例2伤口处有皮肤附属器官新生组织形成(图3)。另外与高硼含量的对比例2相比，实施例2的生物相容性更优(图6)，可更快的促进糖尿病慢性伤口愈合。SD rats weigh about 300-400 g, and there are 6 male rats in each group. SD rats were fasted for 12 h before the experiment. According to the intraperitoneal injection of streptozotocin at a dose of 55mg/kg body weight in SD rats, SD rats showed the characteristics of hyperglycemia (>16.7mmol/L), weight loss, polydipsia, polyphagia and polyuria after 10 days, and successfully established type I diabetes rat model. After the diabetic SD rats with successful modeling were fed for 45 days, the skin wound healing experiment was carried out. Diabetic SD rats were gas anesthetized with isoflurane. After hair removal on the back of diabetic SD rats, povidone iodine disinfection, two full-thickness skin defect models with an inner diameter of 20mm were created on both sides of the back with a circular mold. Negative blank control group is applied with physiological saline, the experimental group is the boron-containing bioactive glass gel prepared in Example 1-3, and the positive control group is the bioactive glass gel without bioactive glass gel and comparative example 1; wound smear After materials, the wounds were sealed with Tegaderm TM Film (3M), and then elastic bandages were used to fix the wounds. The dressing was changed every 3-4 days, and the wound healing was observed. HE staining of wound site tissues was performed on
测试例3
本测试例测试了不同材料促进角化细胞迁移情况的影响。This test case tests the effect of different materials on promoting the migration of keratinocytes.
按照0.2g/mL的浸提标准，将样品与无血清培养基混合，置于37℃摇床浸提24h。然后在超净台将浸提液用无菌滤膜过滤至无菌的离心管，制备得到无菌的样品浸提液。复苏东人类永生化表皮细胞(HaCaT细胞)，经过2～3次传代，细胞活力恢复后进行下续实验。使用marker笔和直尺在6孔板背后，过圆心均匀得画两条相互垂直的直线；每孔加入5×105个细胞，培养24h，待细胞铺贴壁满整个底面后，用无菌枪头，垂直细胞平面，沿着之前用marker笔设计的划痕进行划线。每孔加入适量无菌PBS清洗2～3次，轻轻震动孔板，洗去未贴壁以及划痕时划下的细胞，在显微镜下观察划痕清晰，且划痕中间无细胞残留，用荧光显微镜明场拍照记录。根据试验的设置，对孔板和样品进行分组，将样品浸提液(无血清)加入孔板进行培养。将细胞放入37℃、5％CO2培养箱培养24h，取出培养板，用荧光显微镜明场观察划痕，与24h前及空白对照组的划痕进行比较。图4表明相比空白组、不含生物活性玻璃凝胶组和生物活性玻璃凝胶组(对比例1)，含硼生物活性玻璃凝胶组(I、II和III)均显著促进了角化细胞的迁移，尤其是含硼生物活性玻璃II组。进一步验证了体内含硼生物活性玻璃凝胶促进创面表皮快速形成，从而促进创面愈合的疗效。According to the extraction standard of 0.2g/mL, the sample was mixed with serum-free medium, and placed in a shaker at 37°C for 24 hours. Then filter the extract solution into a sterile centrifuge tube with a sterile filter membrane in an ultra-clean bench to prepare a sterile sample extract solution. The human immortalized epidermal cells (HaCaT cells) were resuscitated. After 2-3 passages, the cell viability was recovered and the next experiment was carried out. Use a marker pen and a ruler to draw two perpendicular straight lines on the back of the 6-well plate evenly through the center of the circle; add 5×10 5 cells to each well and culture for 24 hours. The tip of the pipette is perpendicular to the cell plane, and is drawn along the scratches designed with the marker pen. Add an appropriate amount of sterile PBS to each well to wash 2 to 3 times, shake the well plate gently, and wash away the unattached and scratched cells. The scratches are clear under the microscope, and no cells remain in the middle of the scratches. Fluorescence microscopy bright field photographs and records. According to the setting of the experiment, the well plates and samples are grouped, and the sample extract (serum-free) is added to the well plates for incubation. The cells were cultured in a 37°C, 5% CO 2 incubator for 24 hours, the culture plate was taken out, and the scratches were observed with a fluorescent microscope in bright field, and compared with the scratches of the blank control group and before 24 hours. Figure 4 shows that compared with the blank group, no bioactive glass gel group and bioactive glass gel group (comparative example 1), boron-containing bioactive glass gel groups (I, II and III) all significantly promote keratinization Migration of cells, especially boron-containing bioactive glass group II. It further verified the curative effect of boron-containing bioactive glass gel in promoting the rapid formation of wound epidermis, thereby promoting wound healing.
测试例4Test case 4
本测试例测试了不同材料体外对金黄色葡萄球菌抑菌情况的影响。This test case tested the effect of different materials on the antibacterial situation of Staphylococcus aureus in vitro.
将材料平铺满6孔板孔底，然后加入2mL含有金黄色葡萄球菌的LB培养基(1×106CFU)至每个孔中(n＝5)。在37℃下培养箱中孵育24h后，以100rpm的速度旋转振动孔板，吸取100μL培养基，测定悬液在600nm处的吸光度。材料对金黄色葡萄球菌的抑制率＝(A1-A0)/A0×100％。A0是空白对照组的吸光度，A1为实验组组的吸光度。图5表明相比空白组、不含生物活性玻璃凝胶组和生物活性玻璃凝胶组(对比例1)，含硼生物活性玻璃凝胶组(I和III)均具有显著的抑制金黄色葡萄球菌的抑菌作用。The material was evenly spread to the bottom of the 6-well plate, and then 2 mL of LB medium (1×10 6 CFU) containing Staphylococcus aureus was added to each well (n=5). After incubating in an incubator at 37° C. for 24 h, the vibrating plate was rotated at a speed of 100 rpm, 100 μL of medium was drawn, and the absorbance of the suspension at 600 nm was measured. Inhibition rate of materials against Staphylococcus aureus=(A1-A0)/A0×100%. A0 is the absorbance of the blank control group, and A1 is the absorbance of the experimental group. Figure 5 shows that compared with the blank group, no bioactive glass gel group and bioactive glass gel group (comparative example 1), boron-containing bioactive glass gel groups (I and III) all have significant inhibition of grapevine aureus Bacteriostatic effect of cocci.
测试例5Test case 5
本测试例测试了不同材料体外细胞毒性情况的影响。This test case tests the influence of different materials on the cytotoxicity in vitro.
根据国标GB/T 16886.5-2017体外细胞毒性试验，本测试例测试了不同含硼生物活性玻璃凝胶材料对L929成纤维细胞的细胞毒性情况。利用CCK-8试剂盒评估含硼生物活性玻璃凝胶浸提液与L929成纤维细胞的生物相容性。L929细胞在培养基(DMEM/FBS，9:1)中于37℃、5％ CO2中培养。将100μL L929细胞悬浮液(5×103cells/cm-2)添加到96孔板中并培养24h。移除培养基，将100μL材料提取物(0.2g/mL)添加到96孔板中。然后，将孔板置于37℃的5％ CO2中培养24h。根据说明添加CCK-8试剂。使用微孔板读取器在450nm处记录样品的吸光度，细胞存活率采用公式[|(A-A0)|/A0×100％]，A为样品的吸光度，A0为培养基空白组吸光度。图6表明所制备的含硼生物活性玻璃凝胶材料符合国标GB/T 16886.5-2017体外细胞毒性试验要求，细胞相容性良好。According to the national standard GB/T 16886.5-2017 in vitro cytotoxicity test, this test example tested the cytotoxicity of different boron-containing bioactive glass gel materials on L929 fibroblasts. The biocompatibility of boron-containing bioactive glass gel extract with L929 fibroblasts was evaluated by CCK-8 kit. L929 cells were cultured in medium (DMEM/FBS, 9:1) at 37°C, 5% CO 2 . 100 μL of L929 cell suspension (5×10 3 cells/cm -2 ) was added to a 96-well plate and cultured for 24 hours. The medium was removed and 100 μL of material extract (0.2 g/mL) was added to the 96-well plate. Then, the plate was incubated at 37 °C in 5% CO 2 for 24 h. Add CCK-8 reagent according to the instructions. Use a microplate reader to record the absorbance of the sample at 450nm. The cell viability adopts the formula [|(AA 0 )|/A 0 ×100%], A is the absorbance of the sample, and A 0 is the absorbance of the medium blank group. Figure 6 shows that the prepared boron-containing bioactive glass gel material meets the requirements of the national standard GB/T 16886.5-2017 in vitro cytotoxicity test, and has good cytocompatibility.
测试例6Test case 6
本测试例测试了不同材料体外溶血性能的影响。This test case tests the influence of different materials on hemolytic performance in vitro.
本测试例测试了不同含硼生物活性玻璃凝胶材料对红细胞溶血率的影响情况。采集健康新西兰白兔耳缘动脉血液，置于含有抗凝剂枸橼酸钠的采血管中。取新鲜抗凝兔血8mL，加入生理盐水10mL进行稀释。供试品组每组3支试管，每管中加入供试品5g及生理盐水10mL；阴性对照组3支试管，每管加入生理盐水10mL；阳性对照管组3支试管，每管加入蒸馏水10mL。全部试管置于(37℃±1℃)恒温水浴中保温30min后，每支试管加入0.2mL上述稀释的兔血，轻轻摇匀，置于(37℃±1℃)恒温水浴中继续保温60min。倒出管内液体置于15mL离心管中，于800g下离心15min。吸取上清液移入比色皿内，按照分光光度法(中国药典四部通则0401)，于545nm波长处测定吸光度。供试品组合对照组吸光度均取3支管的平均值，阴性对照管的吸光度应不大于0.03，阳性对照组吸光度应为0.8±0.03，否则重新试验。按下式子进行计算：In this test case, the influence of different boron-containing bioactive glass gel materials on the hemolysis rate of red blood cells was tested. Blood was collected from healthy New Zealand white rabbits' ear border arteries and placed in blood collection tubes containing anticoagulant sodium citrate. Take 8 mL of fresh anticoagulated rabbit blood and add 10 mL of normal saline for dilution. 3 test tubes in each test group, 5 g of test product and 10 mL of normal saline in each tube; 3 test tubes in negative control group, 10 mL of normal saline in each tube; 3 test tubes in positive control group, 10 mL of distilled water in each tube . After all the test tubes were kept in a constant temperature water bath (37°C±1°C) for 30 minutes, add 0.2mL of the above-mentioned diluted rabbit blood to each test tube, shake it gently, and place it in a constant temperature water bath (37°C±1°C) for 60 minutes. . Pour out the liquid in the tube and place it in a 15mL centrifuge tube, and centrifuge at 800g for 15min. The supernatant was drawn and transferred into a cuvette, and the absorbance was measured at a wavelength of 545 nm according to the spectrophotometric method (Chinese Pharmacopoeia Four General Rules 0401). The absorbance of the test product combination control group is the average value of 3 tubes, the absorbance of the negative control tube should not be greater than 0.03, and the absorbance of the positive control group should be 0.8±0.03, otherwise the test should be repeated. Calculate according to the formula:
溶血率＝(供试品吸光度-阴性对照组吸光度)/(阳性对照组吸光度-阴性对照组吸光度)×100％。溶血率小于5％则判定为血液相容性良好。图7表明所制备的含硼生物活性玻璃凝胶材料溶血率均小于5％，血液相容性良好。Hemolysis rate=(absorbance of test product-absorbance of negative control group)/(absorbance of positive control group-absorbance of negative control group)×100%. When the hemolysis rate is less than 5%, it is judged that the blood compatibility is good. Fig. 7 shows that the hemolysis rate of the prepared boron-containing bioactive glass gel material is less than 5%, and the hemocompatibility is good.
上面结合附图对本发明实施例作了详细说明，但是本发明不限于上述实施例，在所属技术领域普通技术人员所具备的知识范围内，还可以在不脱离本发明宗旨的前提下作出各种变化。此外，在不冲突的情况下，本发明的实施例及实施例中的特征可以相互组合。The embodiments of the present invention have been described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned embodiments, and within the scope of knowledge of those of ordinary skill in the art, various modifications can be made without departing from the spirit of the present invention. Variety. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other if there is no conflict.
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310406166.2A CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
| PCT/CN2023/121103 WO2024207695A1 (en) | 2023-04-06 | 2023-09-25 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310406166.2A CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116354599A true CN116354599A (en) | 2023-06-30 |
Family
ID=86908282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310406166.2A Pending CN116354599A (en) | 2023-04-06 | 2023-04-06 | Boron-containing bioactive glass and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116354599A (en) |
| WO (1) | WO2024207695A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024207695A1 (en) * | 2023-04-06 | 2024-10-10 | 深圳先进技术研究院 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259277A (en) * | 2008-04-25 | 2008-09-10 | 同济大学 | A novel orthopedic drug carrier system and preparation method thereof |
| CN102657893A (en) * | 2012-05-07 | 2012-09-12 | 浙江大学 | Medical nano-fiber sponge material and preparation method and application thereof |
| CN107510704A (en) * | 2017-10-18 | 2017-12-26 | 张家港蓝智生物科技有限公司 | A kind of antiallergy burn and scald paste containing bio-vitric |
| CN107617121A (en) * | 2017-10-13 | 2018-01-23 | 广州润虹医药科技股份有限公司 | A kind of skin wound biology induced activity dressing and its preparation method and application |
| CN109437559A (en) * | 2018-11-19 | 2019-03-08 | 湖北中创医疗用品有限公司 | Bioactivity glass, bioactivity glass gel and its preparation method and application |
| CN113171224A (en) * | 2021-04-08 | 2021-07-27 | 浙江大学 | An implanted bandage for promoting bone injury repair and preparation method thereof |
| CN113599574A (en) * | 2021-07-28 | 2021-11-05 | 苏州大学 | Regeneration material for muscle repair and preparation method thereof |
| CN113698560A (en) * | 2021-09-13 | 2021-11-26 | 深圳先进技术研究院 | Antibacterial and anti-inflammatory composite hydrogel precursor solution and preparation method and application thereof |
| CN114524612A (en) * | 2022-02-10 | 2022-05-24 | 深圳市中科海世御生物科技有限公司 | Amorphous silicon-based material and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103848574A (en) * | 2012-12-06 | 2014-06-11 | 上海诺帮生物科技有限公司 | Preparation of strontium-containing bioglass powder and preparation method of strontium-containing porous bioglass bracket |
| US20150283300A1 (en) * | 2014-04-03 | 2015-10-08 | Gregory J. Pomrink | Bioactive glasses with surface immobilized peptides and uses thereof |
| US10751367B2 (en) * | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
| CN109020230A (en) * | 2018-09-28 | 2018-12-18 | 吉林省米阳光医疗器械科技有限公司 | A kind of magnesium, strontium-reinforced bioactive glass ceramic |
| CN116354599A (en) * | 2023-04-06 | 2023-06-30 | 深圳先进技术研究院 | Boron-containing bioactive glass and preparation method and application thereof |
-
2023
- 2023-04-06 CN CN202310406166.2A patent/CN116354599A/en active Pending
- 2023-09-25 WO PCT/CN2023/121103 patent/WO2024207695A1/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101259277A (en) * | 2008-04-25 | 2008-09-10 | 同济大学 | A novel orthopedic drug carrier system and preparation method thereof |
| CN102657893A (en) * | 2012-05-07 | 2012-09-12 | 浙江大学 | Medical nano-fiber sponge material and preparation method and application thereof |
| CN107617121A (en) * | 2017-10-13 | 2018-01-23 | 广州润虹医药科技股份有限公司 | A kind of skin wound biology induced activity dressing and its preparation method and application |
| CN107510704A (en) * | 2017-10-18 | 2017-12-26 | 张家港蓝智生物科技有限公司 | A kind of antiallergy burn and scald paste containing bio-vitric |
| CN109437559A (en) * | 2018-11-19 | 2019-03-08 | 湖北中创医疗用品有限公司 | Bioactivity glass, bioactivity glass gel and its preparation method and application |
| CN113171224A (en) * | 2021-04-08 | 2021-07-27 | 浙江大学 | An implanted bandage for promoting bone injury repair and preparation method thereof |
| CN113599574A (en) * | 2021-07-28 | 2021-11-05 | 苏州大学 | Regeneration material for muscle repair and preparation method thereof |
| CN113698560A (en) * | 2021-09-13 | 2021-11-26 | 深圳先进技术研究院 | Antibacterial and anti-inflammatory composite hydrogel precursor solution and preparation method and application thereof |
| CN114524612A (en) * | 2022-02-10 | 2022-05-24 | 深圳市中科海世御生物科技有限公司 | Amorphous silicon-based material and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| JINGXIN DING 等: "Regulated contribution of local and systemic immunity to new bone regeneration by modulating B/Sr concentration of bioactive borosilicate glass", 《MATERIALS TODAY BIO》, pages 1 - 15 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024207695A1 (en) * | 2023-04-06 | 2024-10-10 | 深圳先进技术研究院 | Boron-containing bioactive glass, and preparation method therefor and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024207695A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kargozar et al. | Can bioactive glasses be useful to accelerate the healing of epithelial tissues? | |
| Yang et al. | Sustained release of magnesium and zinc ions synergistically accelerates wound healing | |
| Mehrabi et al. | Bioactive glasses: a promising therapeutic ion release strategy for enhancing wound healing | |
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN101104080B (en) | Zeolite hemostatic dressing and its preparation method and application | |
| CN103736135B (en) | A kind of medical composite dressing and preparation method thereof | |
| CN101301487A (en) | Gelatine/biological activity glass composite sponge dressing and preparation thereof | |
| Shen et al. | Improved BMP2-CPC-stimulated osteogenesis in vitro and in vivo via modulation of macrophage polarization | |
| CN113648454A (en) | Hydrogel dressing carrying metal-polyphenol functional particles and preparation method and application thereof | |
| CN116354599A (en) | Boron-containing bioactive glass and preparation method and application thereof | |
| CN113511811A (en) | A kind of multifunctional mesoporous biological material, preparation method and application | |
| CN108261557B (en) | A kind of nanofiber membrane for wound healing and its preparation method and application | |
| Zhang et al. | Cobalt-containing borate bioactive glass fibers for treatment of diabetic wound | |
| WO2019148554A1 (en) | Boron and phosphorus-based bioactive glass and preparation method thereof | |
| CN108404224A (en) | Preparation method and application of borosilicate bioglass/polyvinyl alcohol hybrid hydrogel | |
| Chang et al. | A bioartificial dermal regeneration template promotes skin cell proliferation in vitro and enhances large skin wound healing in vivo | |
| CN113616849B (en) | Liquid dressing for external wound care and preparation method thereof | |
| CN118987333A (en) | Wound healing material and preparation method thereof | |
| CN102552323B (en) | Medicine for accelerating skin repair and regeneration, preparation method thereof and application thereof | |
| Miguez-Pacheco et al. | Bioactive glasses for soft tissue engineering applications | |
| Zhu et al. | Effectiveness of nano bioactive glass fiber loaded with platelet-rich plasma on thermal wound healing process in rats | |
| CN109793757B (en) | Composition for inhibiting growth of skin scar and preparation method and application thereof | |
| Kayal et al. | Microfibers of fish waste-derived collagen and ion-doped bioactive glass in stimulating the healing sequences in full-thickness cutaneous burn injury | |
| CN107149701A (en) | Carry type i collagen/calcium hydroxy apetite Bionics Bone of carbapenem antibiotic | |
| Tamisani et al. | Critical reflections on the use of human cultured keratinocytes in children with burns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |